ABVC BioPharma Receives $450,000 from OncoX in Q3 2025, Underscoring Partnership's Commercial Potential

ABVC BioPharma received $450,000 in licensing payments from OncoX BioPharma in Q3 2025, including $350,000 in August. The payments underscore the strength of the companies' strategic alliance and the growing commercial potential of ABVC's oncology pipeline. Under the licensing agreements, ABVC is entitled to 5 million OncoX shares and $2.5 million in cash payments, plus royalties. The total potential deal proceeds amount to $105 million.

Silicon Valley, CA - August 29, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CNS) disorders, announced today that its partner OncoX BioPharma has delivered $450,000 in licensing payments in the third quarter of 2025, including $350,000 received in August. These payments underscore the strength of the companies' strategic alliance and the growing commercial potential of ABVC's oncology pipeline.

Under the licensing agreements with OncoX, ABVC is entitled to 5,000,000 OncoX shares and $2,500,000 in cash payments, plus royalties. To date, ABVC has received $650,000 in cash (including $200,000 in 2024 and $450,000 in Q3 2025), with $1,850,000 remaining in receivable cash and its 5,000,000 OncoX shares secured. The licensing payment and equity summary between ABVC and OncoX shows a total potential deal proceeds of $105 million.

The OncoX collaboration covers four major oncology indications: Triple Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC), Myelodysplastic Syndromes (MDS), and Pancreatic Cancer. All four indications have received FDA IND (Investigational New Drug) approvals, demonstrating ABVC's strong development position in botanical-derived oncology drug candidates.

According to Precedence Research, the global cancer therapeutics market was valued at approximately US$164 billion in 2022 and is projected to reach US$393 billion by 2032, representing a CAGR of 9.2%[1]. Another forecast estimates the market at US$194.67 billion in 2024, expanding to US$469.38 billion by 2034, also at a CAGR of 9.2%[2]. These figures highlight the substantial commercial opportunity for ABVC and BioLite through their partnership with OncoX.

Dr. Uttam Patil, ABVC's Chief Executive Officer, stated: "The $450,000 received from OncoX this quarter, including $350,000 in August, demonstrates the execution strength of our collaboration. At the ABVC standalone level, we have secured $650,000 in cash receipts to date, with $1.85 million still receivable and 5 million OncoX shares in hand. When viewed at the Group level, including our subsidiary BioLite, ABVC collectively is entitled to $3.75 million in total cash consideration and 7.5 million OncoX shares. This broader perspective highlights not only immediate liquidity but also the long-term equity value embedded in our partnership with OncoX."

Mr. Yen, Chief Executive Officer of OncoX BioPharma, added: "Our partnership with ABVC reflects our vision of combining innovation with strategic collaborations to create long-term value. According to industry research, the global cancer therapeutics market was valued at approximately US$194.67 billion in 2024 and is projected to expand to US$469.38 billion by 2034, growing at a CAGR of 9.2%[3]. Against this backdrop, our licensing agreement with ABVC, together with our acquisition of the Lycogen® platform for $4.06 million, demonstrates our commitment to expanding our oncology portfolio and preparing for global market opportunities."

This licensing partnership with OncoX strengthens ABVC’s strategic positioning in oncology. By combining immediate and potential cash inflows, equity holdings, and future royalty streams, ABVC has created a framework with a consolidated value exceeding $41 million (excluding royalties). We believe this collaboration further cements ABVC’s leadership in advancing botanical-derived oncology therapeutics toward global commercialization.

References:
[1] https://www.precedenceresearch.com/cancer-therapeutics-market?utm_source=chatgpt.com
[2] https://www.precedenceresearch.com/cancer-therapeutics-market?utm_source=chatgpt.com
[3] https://www.precedenceresearch.com/cancer-therapeutics-market?utm_source=chatgpt.com